183 related articles for article (PubMed ID: 27608007)
1. Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients.
Dreussi E; Cecchin E; Polesel J; Canzonieri V; Agostini M; Boso C; Belluco C; Buonadonna A; Lonardi S; Bergamo F; Gagno S; De Mattia E; Pucciarelli S; De Paoli A; Toffoli G
Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27608007
[TBL] [Abstract][Full Text] [Related]
2. X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients.
Lamas MJ; Duran G; Gomez A; Balboa E; Anido U; Bernardez B; Rana-Diez P; Lopez R; Carracedo A; Barros F
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):138-44. PubMed ID: 21167658
[TBL] [Abstract][Full Text] [Related]
3. Tumor microRNAs Identified by Small RNA Sequencing as Potential Response Predictors in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy.
Machackova T; Trachtova K; Prochazka V; Grolich T; Farkasova M; Fiala L; Sefr R; Kiss I; Skrovina M; Dosoudil M; Berindan-Neagoe I; Svoboda M; Slaby O; Kala Z
Cancer Genomics Proteomics; 2020; 17(3):249-257. PubMed ID: 32345666
[TBL] [Abstract][Full Text] [Related]
4. Impact of single-nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD-12/PRODIGE-2 phase III trial.
Boige V; Mollevi C; Gourgou S; Azria D; Seitz JF; Vincent M; Bigot L; Juzyna B; Miran I; Gerard JP; Laurent-Puig P
Int J Cancer; 2019 Dec; 145(11):3163-3172. PubMed ID: 31107542
[TBL] [Abstract][Full Text] [Related]
5. The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.
Martinez-Useros J; Moreno I; Fernandez-Aceñero MJ; Rodriguez-Remirez M; Borrero-Palacios A; Cebrian A; Gomez Del Pulgar T; Del Puerto-Nevado L; Li W; Puime-Otin A; Perez N; Soengas MS; Garcia-Foncillas J
BMC Cancer; 2018 Feb; 18(1):144. PubMed ID: 29409457
[TBL] [Abstract][Full Text] [Related]
6. Circulating serum microRNA-345 correlates with unfavorable pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer.
Yu J; Li N; Wang X; Ren H; Wang W; Wang S; Song Y; Liu Y; Li Y; Zhou X; Luo A; Liu Z; Jin J
Oncotarget; 2016 Sep; 7(39):64233-64243. PubMed ID: 27572313
[TBL] [Abstract][Full Text] [Related]
7. Predicting response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer with serum biomarkers.
Clarke TL; White DA; Osborne ME; Shaw AM; Smart NJ; Daniels IR
Ann R Coll Surg Engl; 2017 May; 99(5):373-377. PubMed ID: 28462648
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-31 Emerges as a Predictive Biomarker of Pathological Response and Outcome in Locally Advanced Rectal Cancer.
Caramés C; Cristobal I; Moreno V; Marín JP; González-Alonso P; Torrejón B; Minguez P; Leon A; Martín JI; Hernández R; Pedregal M; Martín MJ; Cortés D; García-Olmo D; Fernández MJ; Rojo F; García-Foncillas J
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27271609
[TBL] [Abstract][Full Text] [Related]
9. Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.
Dreussi E; Pucciarelli S; De Paoli A; Polesel J; Canzonieri V; Agostini M; Friso ML; Belluco C; Buonadonna A; Lonardi S; Zanusso C; De Mattia E; Toffoli G; Cecchin E
Oncotarget; 2016 Apr; 7(15):19781-93. PubMed ID: 26934318
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.
Balboa E; Duran G; Lamas MJ; Gomez-Caamaño A; Celeiro-Muñoz C; Lopez R; Carracedo A; Barros F
Pharmacogenomics; 2010 Jun; 11(6):747-61. PubMed ID: 20504250
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.
Páez D; Salazar J; Paré L; Pertriz L; Targarona E; del Rio E; Barnadas A; Marcuello E; Baiget M
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1319-27. PubMed ID: 21570215
[TBL] [Abstract][Full Text] [Related]
12. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER
Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients.
Lopes-Ramos CM; Habr-Gama A; Quevedo Bde S; Felício NM; Bettoni F; Koyama FC; Asprino PF; Galante PA; Gama-Rodrigues J; Camargo AA; Perez RO; Parmigiani RB
BMC Med Genomics; 2014 Dec; 7():68. PubMed ID: 25496125
[TBL] [Abstract][Full Text] [Related]
14. Systematic Review of Candidate Single-nucleotide Polymorphisms as Biomarkers for Responsiveness to Neoadjuvant Chemoradiation for Rectal Cancer.
Maring ED; Tawadros PS; Steer CJ; Lee JT
Anticancer Res; 2015 Jul; 35(7):3761-6. PubMed ID: 26124319
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and Therapeutic Potential Implications of Genetic Variability in Prostaglandin E2 Pathway Genes in Rectal Cancer.
Santos MD; Silva C; Rocha A; Nogueira C; Castro-Poças F; Araujo A; Matos E; Pereira C; Medeiros R; Lopes C
Anticancer Res; 2017 Jan; 37(1):281-291. PubMed ID: 28011504
[TBL] [Abstract][Full Text] [Related]
16. Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis.
An X; Lin X; Wang FH; Goodman K; Cai PQ; Kong LH; Fang YJ; Gao YH; Lin JZ; Wan DS; Pan ZZ; Ding PR
Eur J Cancer; 2013 Mar; 49(4):843-51. PubMed ID: 23063351
[TBL] [Abstract][Full Text] [Related]
17. New application of dual point 18F-FDG PET/CT in the evaluation of neoadjuvant chemoradiation response of locally advanced rectal cancer.
Yoon HJ; Kim SK; Kim TS; Im HJ; Lee ES; Kim HC; Park JW; Chang HJ; Choi HS; Kim DY; Oh JH
Clin Nucl Med; 2013 Jan; 38(1):7-12. PubMed ID: 23242038
[TBL] [Abstract][Full Text] [Related]
18. Genetic variations using whole-exome sequencing might predict response for neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
Lee IH; Kang K; Kang BW; Lee SJ; Bae WK; Hwang JE; Kim HJ; Park SY; Park JS; Choi GS; Kim JG
Med Oncol; 2018 Sep; 35(11):145. PubMed ID: 30206710
[TBL] [Abstract][Full Text] [Related]
19. Germline and somatic genetic predictors of pathological response in neoadjuvant settings of rectal and esophageal cancers: systematic review and meta-analysis.
Salnikova LE; Kolobkov DS
Pharmacogenomics J; 2016 Jun; 16(3):249-65. PubMed ID: 26122021
[TBL] [Abstract][Full Text] [Related]
20. Locally advanced rectal cancer transcriptomic-based secretome analysis reveals novel biomarkers useful to identify patients according to neoadjuvant chemoradiotherapy response.
Canto LMD; Cury SS; Barros-Filho MC; Kupper BEC; Begnami MDFS; Scapulatempo-Neto C; Carvalho RF; Marchi FA; Olsen DA; Madsen JS; Havelund BM; Aguiar S; Rogatto SR
Sci Rep; 2019 Jun; 9(1):8702. PubMed ID: 31213644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
